Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMO’s last independent quarter

This article was originally published in The Tan Sheet

Executive Summary

Advanced Medical Optics' fiscal 2008 net sales rose 8.6 percent to $1.2 billion despite net sales falling 6.4 percent to $285.2 million in the fourth quarter. The Santa Ana, Calif.-based firm says Feb. 20 that the quarterly drop primarily was due to poor refractive sales, which fell 24.8 percent to $87.1 million in the quarter because consumers have less discretionary money for eye procedures. However, eye-care product sales rose 8.3 percent to $54.7 million in the quarter, led by a 21.9 percent increase in multipurpose solution sales to $24.5 million and by sales of artificial tears, part of the "other" category, which was up 12.3 percent to $15 million. Abbott is acquiring AMO for $22 per share in cash for a total $2.8 billion (1"The Tan Sheet" Feb. 9, 2009, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel